47 results on '"SURROGATE ENDPOINT"'
Search Results
2. Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer
3. Short-term OS as a surrogate endpoint for 5-year OS in nasopharyngeal carcinoma in non-endemic area
4. Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
5. Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma
6. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials
7. eGFR slope as a surrogate endpoint for end-stage kidney disease in patients with diabetes and eGFR > 30 mL/min/1.73 m2 in the J-DREAMS cohort
8. Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review
9. Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis
10. eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database
11. Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization
12. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings
13. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis
14. Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach
15. Food and Drug Administration approvals in phase 3 Cancer clinical trials
16. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
17. Evaluation of Selective Outcome Reporting Bias in Efficacy Endpoints in Print and Television Advertisements for Oncology Drugs
18. Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer
19. Event Surrogate from Clinical Pathway Completion to Daily Meal for Availability Extension Using Standard Electronic Medical Records: a Retrospective Cohort Study
20. Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis
21. Guidelines for clinical evaluation of chronic kidney disease: AMED research on regulatory science of pharmaceuticals and medical devices
22. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
23. Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study
24. Commentary: The value of intraoperative neurophysiological monitoring: evidence, equipoise and outcomes
25. Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials
26. Bayesian Inferences of Latent Class Models with an Unknown Number of Classes
27. Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer
28. Is critical care ready for an economic surrogate endpoint?
29. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
30. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer
31. Considerations for Endpoint Selection When Designing HIV Clinical Trials
32. Biomarkers in Neurocritical Care
33. Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes
34. When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes
35. Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months
36. The validity of biomarkers as surrogate endpoints in Alzheimer’s disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)
37. Magnetic resonance imaging (MRI)-based indication for neoadjuvant treatment of rectal carcinoma and the surrogate endpoint CRM status
38. Exploring and validating surrogate endpoints in colorectal cancer
39. An introduction to biomarkers: applications to chronic kidney disease
40. Imaging biomarkers as surrogate endpoints for drug development
41. Blood pressure as an example of a biomarker that functions as a surrogate
42. A New Clinical Trial Design Combining Phases 2 and 3: Sequential Designs with Treatment Selection and a Change of Endpoint
43. Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas
44. Toward the Validation of Functional Neuroimaging as a Potential Biomarker for Alzheimer’s Disease: Implications for Drug Development
45. Statistics in clinical trials
46. Statistical Validation of Surrogate Endpoints: Problems and Proposals
47. Prognostische Bedeutung der ST-Strecken-Veränderung beim akuten Myokardinfarkt
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.